ALT IFCC Modified - Research Applications

SCCB method eliminates PLP activation variability across genotype-independent ALT standardization for NAFLD trial endpoints.

Research laboratories achieve CV<2.5% confirming 10% fibrosis discrimination. PLP-free prevents activation artifact in therapeutic monitoring.

Quality control verifies SCCB buffer, zero PLP interference, and IRMM standardization. Reference method prevents clinical bias.